GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Conmed Corp (NYSE:CNMD) » Definitions » ROIC %

Conmed (Conmed) ROIC % : 4.98% (As of Mar. 2024)


View and export this data going back to 1987. Start your Free Trial

What is Conmed ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Conmed's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2024 was 4.98%.

As of today (2024-04-26), Conmed's WACC % is 7.41%. Conmed's ROIC % is 4.36% (calculated using TTM income statement data). Conmed earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Conmed ROIC % Historical Data

The historical data trend for Conmed's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conmed ROIC % Chart

Conmed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.85 16.24 5.59 4.10 4.39

Conmed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.71 3.90 4.27 7.42 4.98

Competitive Comparison of Conmed's ROIC %

For the Medical Devices subindustry, Conmed's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Conmed's ROIC % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Conmed's ROIC % distribution charts can be found below:

* The bar in red indicates where Conmed's ROIC % falls into.



Conmed ROIC % Calculation

Conmed's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=120.603 * ( 1 - 20.25% )/( (2195.257 + 2187.501)/ 2 )
=96.1808925/2191.379
=4.39 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2297.592 - 73.393 - ( 28.942 - max(0, 296.552 - 581.226+28.942))
=2195.257

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2300.021 - 88.224 - ( 24.296 - max(0, 310.729 - 615.649+24.296))
=2187.501

Conmed's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2024 is calculated as:

ROIC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=140.052 * ( 1 - 22.46% )/( (2187.501 + 2173.765)/ 2 )
=108.5963208/2180.633
=4.98 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2300.021 - 88.224 - ( 24.296 - max(0, 310.729 - 615.649+24.296))
=2187.501

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2309.255 - 101.635 - ( 33.855 - max(0, 291.404 - 635.724+33.855))
=2173.765

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Conmed  (NYSE:CNMD) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Conmed's WACC % is 7.41%. Conmed's ROIC % is 4.36% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Conmed ROIC % Related Terms

Thank you for viewing the detailed overview of Conmed's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Conmed (Conmed) Business Description

Traded in Other Exchanges
Address
11311 Concept Boulevard, Largo, FL, USA, 33773
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgery. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.
Executives
Peters Stanley W Iii officer: VP GM General Surgery C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Todd W. Garner officer: Executive Vice President & CFO C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Edward A. Clifford officer: VP Global Manufacturing C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Curt R Hartman director C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
John D. Ferrell officer: Executive Vice President - HR C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Brian Concannon director HAEMONETICS CORP, 400 WOOD RD, BRAINTREE MA 02184-9144
Peter K Shagory officer: EVP,STRAT & CORP DEVT C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Daniel Jonas officer: Vice President/Legal Affairs, other: General Counsel C/O CONMED CORP, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Terence M Berge officer: VP Corp. Treasurer C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Johonna Marie Pelletier officer: Treasurer and VP, Tax C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Jerome J. Lande director 1 WORLD TRADE CENTER, 85TH FLOOR, NEW YORK NY 10007
Brent Lalomia officer: Vice President QA and RA C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
John Jed Kennedy officer: VP GM GI C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Mark E Tryniski director C/O CONMED CORP., 11311 CONCEPT BOULEVARD, LARGO FL 33773
Pat Beyer officer: President-Conmed International C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773